Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer’s disease
Nanaka Kaneshiro(University of California, Riverside), Nobumasa Takasugi(Okayama University), Takaomi C. Saido(RIKEN Center for Brain Science), Ryosuke Imaoka(Okayama University), Takashi Uehara(Okayama University), Tadafumi Hashimoto(Kyushu University), Yuji Kamikubo(Juntendo University), Takashi Sakurai(Juntendo University), Atsuya Ikeda(Okayama University), Takeshi Iwatsubo(National Center of Neurology and Psychiatry), Takashi Saito(Nagoya City University), Taisuke Tomita(The University of Tokyo), Masato Komai(Okayama University)
Cited by 17
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Lecanemab in Early Alzheimer’s Disease
|New England Journal of Medicine|2022|5k
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
|Journal of Neuropathology & Experimental Neurology|2012|2.1k
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
|Nature|2018|1.7k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k